Pure Global AI
NCT06348498Not yet recruiting

Pharmacokinetic and Pharmacodynamic of Jia Shen Tablets in Chronic Heart Failure

A Open Label, Standardise-loaded and Single-Centre Phase Ⅰb Clinical Trial：Pharmacokinetic and Pharmacodynamic of Jia Shen Tablets in Chronic Heart Failure
Tasly Pharmaceutical Group Co., LtdPhase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Heart Failure
Drug/Device/Intervention
Jia Shen Tablet
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Tasly Pharmaceutical Group Co., Ltd
Location
Tianjin, China
Timeline & enrollment
Phase
Phase 1
Start date
Mar 31, 2024
End date
Jun 30, 2026
Enrollment
18 participants
Primary outcome

Pharmacokinetic characteristic evaluation：Maximum observed plasma concentration (Cmax),Plasma PK analysis: Time to reach peak or maximum observed concentration following drug administration (Tmax),Plasma PK analysis: Area under curve at steady state (AUCss)

Summary

Evaluate the pharmacokinetic and pharmacodynamic characteristics of Jia Shen Tablets in
 patients with Chronic Heart Failure.

ICD-10 classifications
Heart failureHeart failure, unspecifiedCongestive heart failureHypertensive heart disease with (congestive) heart failureLeft ventricular failure
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06348498
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06348498 through Pure Global AI's free database. This Phase 1 trial is sponsored by Tasly Pharmaceutical Group Co., Ltd and is currently Not yet recruiting. The study focuses on Heart Failure. Target enrollment is 18 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.